Logo image of IMCR

IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Stock Fundamental Analysis

USA - NASDAQ:IMCR - US45258D1054 - ADR

34.425 USD
+0 (+0.01%)
Last: 9/24/2025, 9:46:22 AM
Fundamental Rating

4

Overall IMCR gets a fundamental rating of 4 out of 10. We evaluated IMCR against 538 industry peers in the Biotechnology industry. IMCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, IMCR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

IMCR had negative earnings in the past year.
In the past year IMCR had a positive cash flow from operations.
IMCR had negative earnings in each of the past 5 years.
In multiple years IMCR reported negative operating cash flow during the last 5 years.
IMCR Yearly Net Income VS EBIT VS OCF VS FCFIMCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With an excellent Return On Assets value of -1.88%, IMCR belongs to the best of the industry, outperforming 88.29% of the companies in the same industry.
With an excellent Return On Equity value of -5.23%, IMCR belongs to the best of the industry, outperforming 89.96% of the companies in the same industry.
Industry RankSector Rank
ROA -1.88%
ROE -5.23%
ROIC N/A
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
IMCR Yearly ROA, ROE, ROICIMCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

With an excellent Gross Margin value of 99.26%, IMCR belongs to the best of the industry, outperforming 97.96% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for IMCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMCR Yearly Profit, Operating, Gross MarginsIMCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

IMCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMCR has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, IMCR has more shares outstanding
The debt/assets ratio for IMCR is higher compared to a year ago.
IMCR Yearly Shares OutstandingIMCR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IMCR Yearly Total Debt VS Total AssetsIMCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

IMCR has an Altman-Z score of 1.57. This is a bad value and indicates that IMCR is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.57, IMCR is doing good in the industry, outperforming 65.61% of the companies in the same industry.
The Debt to FCF ratio of IMCR is 13.78, which is on the high side as it means it would take IMCR, 13.78 years of fcf income to pay off all of its debts.
IMCR's Debt to FCF ratio of 13.78 is amongst the best of the industry. IMCR outperforms 91.64% of its industry peers.
IMCR has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.01, IMCR is not doing good in the industry: 76.39% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 13.78
Altman-Z 1.57
ROIC/WACCN/A
WACC8.68%
IMCR Yearly LT Debt VS Equity VS FCFIMCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

IMCR has a Current Ratio of 5.89. This indicates that IMCR is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.89, IMCR is doing good in the industry, outperforming 62.08% of the companies in the same industry.
A Quick Ratio of 5.86 indicates that IMCR has no problem at all paying its short term obligations.
The Quick ratio of IMCR (5.86) is better than 62.27% of its industry peers.
Industry RankSector Rank
Current Ratio 5.89
Quick Ratio 5.86
IMCR Yearly Current Assets VS Current LiabilitesIMCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.60% over the past year.
Looking at the last year, IMCR shows a very negative growth in Revenue. The Revenue has decreased by -22.69% in the last year.
Measured over the past years, IMCR shows a very strong growth in Revenue. The Revenue has been growing by 64.57% on average per year.
EPS 1Y (TTM)62.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)-22.69%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%30.02%

3.2 Future

The Earnings Per Share is expected to grow by 39.54% on average over the next years. This is a very strong growth
Based on estimates for the next years, IMCR will show a very strong growth in Revenue. The Revenue will grow by 20.06% on average per year.
EPS Next Y20.54%
EPS Next 2Y-11.02%
EPS Next 3Y-1.44%
EPS Next 5Y39.54%
Revenue Next Year25.12%
Revenue Next 2Y17.92%
Revenue Next 3Y16.49%
Revenue Next 5Y20.06%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IMCR Yearly Revenue VS EstimatesIMCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMCR Yearly EPS VS EstimatesIMCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

IMCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCR Price Earnings VS Forward Price EarningsIMCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, IMCR is valued cheaper than 92.38% of the companies in the same industry.
Industry RankSector Rank
P/FCF 60.97
EV/EBITDA N/A
IMCR Per share dataIMCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.02%
EPS Next 3Y-1.44%

More info and screens

0

5. Dividend

5.1 Amount

IMCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOCORE HOLDINGS PLC-ADR

NASDAQ:IMCR (9/24/2025, 9:46:22 AM)

34.425

+0 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners94.14%
Inst Owner Change-3.75%
Ins Owners0.03%
Ins Owner Change0%
Market Cap1.73B
Analysts81.67
Price Target63.68 (84.98%)
Short Float %18.67%
Short Ratio30.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.74%
Min EPS beat(2)0.3%
Max EPS beat(2)125.17%
EPS beat(4)3
Avg EPS beat(4)48.38%
Min EPS beat(4)-79.43%
Max EPS beat(4)147.46%
EPS beat(8)5
Avg EPS beat(8)35.65%
EPS beat(12)7
Avg EPS beat(12)-206113%
EPS beat(16)9
Avg EPS beat(16)-154577%
Revenue beat(2)2
Avg Revenue beat(2)2.92%
Min Revenue beat(2)1.34%
Max Revenue beat(2)4.49%
Revenue beat(4)2
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-4.08%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)-0.07%
Revenue beat(12)7
Avg Revenue beat(12)3.9%
Revenue beat(16)11
Avg Revenue beat(16)25.29%
PT rev (1m)3.92%
PT rev (3m)4.42%
EPS NQ rev (1m)6.61%
EPS NQ rev (3m)2.31%
EPS NY rev (1m)0%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)1.2%
Revenue NQ rev (3m)6.18%
Revenue NY rev (1m)-1.63%
Revenue NY rev (3m)2.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.87
P/FCF 60.97
P/OCF 51.66
P/B 4.47
P/tB 4.47
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)0.56
FCFY1.64%
OCF(TTM)0.67
OCFY1.94%
SpS7.07
BVpS7.71
TBVpS7.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.88%
ROE -5.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.26%
FCFM 7.99%
ROA(3y)-7.93%
ROA(5y)-20.99%
ROE(3y)-14.64%
ROE(5y)-50.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF 13.78
Debt/EBITDA N/A
Cap/Depr 133.61%
Cap/Sales 1.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.89
Quick Ratio 5.86
Altman-Z 1.57
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)97.19%
Cap/Depr(5y)68.03%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y20.54%
EPS Next 2Y-11.02%
EPS Next 3Y-1.44%
EPS Next 5Y39.54%
Revenue 1Y (TTM)-22.69%
Revenue growth 3Y127.06%
Revenue growth 5Y64.57%
Sales Q2Q%30.02%
Revenue Next Year25.12%
Revenue Next 2Y17.92%
Revenue Next 3Y16.49%
Revenue Next 5Y20.06%
EBIT growth 1Y54.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.66%
EBIT Next 3Y-13.65%
EBIT Next 5Y35.12%
FCF growth 1Y82.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.54%
OCF growth 3YN/A
OCF growth 5YN/A